SCHEMBL20420764

SCHEMBL20420764

COc1ccc2c(-c3ccc(-c4ccccc4OC)o3)cc(=O)oc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 1/20 0.57
▸ KMT2A Q03164 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ ALDH1A1 P00352 6/20 0.53
▸ KDM4E B2RXH2 5/20 0.53
▸ HPGD P15428 3/20 0.53
▸ HSD17B10 Q99714 3/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ MAOA P21397 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ GLA P06280 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ KCNA3 P22001 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ NOD2 Q9HC29 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20420716 0.87 ALDH1A1 (0.52) ARKMT2AMEN1ALDH1A1KDM4E
SCHEMBL20428394 0.83 ALDH1A1 (0.48) ARKMT2AMEN1ALDH1A1KDM4E
SCHEMBL20428335 0.83 APP (0.52) ARKMT2AMEN1ALDH1A1KDM4E
SCHEMBL20420805 0.83 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1KDM4EHPGD
SCHEMBL14424527 0.81 KDM4E (0.73) ALDH1A1KDM4EHPGDHSD17B10L3MBTL1
SCHEMBL20420766 0.81 KDM4E (0.57) KMT2AALDH1A1KDM4EHPGDHSD17B10
7,2'-Dimethoxyflavone SCHEMBL4285153 0.81 AR (0.81) ARKMT2AMEN1ALDH1A1KDM4E
SCHEMBL20420733 0.80 MAOB (0.64) KMT2AMEN1ALDH1A1KDM4EHPGD
SCHEMBL30231784 0.79 KDM4E (0.67) KMT2AMEN1ALDH1A1KDM4EHPGD
SCHEMBL20420725 0.79 NOD2 (0.54) KMT2AMEN1ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108349959-B 4-substituted coumarin derivative and preparation method and application thereof 成都赜灵生物医药科技有限公司 2021-11-16 — — CN disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 — — US disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 — — US disclosed
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2018-10-04 — — US disclosed
EP-3354648-A1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) 2018-08-01 — — EP disclosed
EP-3354648-A1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) 2018-08-01 — — EP disclosed
CN-108349959-A The coumarin derivative and its preparation method and application of 4 substitutions 贵州百灵企业集团制药股份有限公司 2018-07-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof MAP4, TUBA3C, ABCC1 AR 4104/4885KMT2A 4058/4885MEN1 2940/4885
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF MAP4, TUBA3C, ABCC1 AR 4104/4885KMT2A 4058/4885MEN1 2940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback